Bioprocess

Global L-Carnitine Market Report 2021: Size, Share & Trends Analysis by Process (Bioprocess, Chemical Synthesis), Product (Food & Pharmaceutical Grade, Feed Grade) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 15, 2021
Pharmaceutical, Health, Fitness & Nutrition, Cayman Chemical Company, CGMP, Awareness, CAGR, Ajinomoto, Growth, ISO, Merck Group, Infertility, Weight, USD, Enzyme, Male, Process, Contract, Food, SSOP, Application, Bioprocess, Research, Degenerative disease, Fine chemical, Agriculture

The "L-Carnitine Market Size, Share & Trends Analysis Report by Process (Bioprocess, Chemical Synthesis), by Product (Food & Pharmaceutical Grade, Feed Grade), by Application, by Region, and Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "L-Carnitine Market Size, Share & Trends Analysis Report by Process (Bioprocess, Chemical Synthesis), by Product (Food & Pharmaceutical Grade, Feed Grade), by Application, by Region, and Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global L-carnitine market size is expected to reach USD 276.0 million by 2028, expanding at a CAGR of 5.1%.
  • Growing consumer awareness regarding product benefits, along with increasing demand from end-use industries such as pharmaceutical, nutraceutical, and animal feed, is projected to drive the market over the forecast period.
  • L-carnitine and its derivatives are used for numerous applications including male infertility, kidney treatment, cardiovascular diseases, weight reduction, and bone mass.

Culture Biosciences Raises $80M Series B to Tackle Demand for Large-Scale Biomanufacturing

Retrieved on: 
Thursday, October 14, 2021
Software, Research, Networks, Internet, Data Management, Technology, Clinical Trials, Science, Engineering, Biotechnology, Manufacturing, Health, Cloud, Section 32, Technology, 5L, Time, Bioprocess, Bioproducts, List of life sciences, Black box group, War Production Board, Business, Synthetic biology, Verily, Section, Fermentation, Craft Ventures, Production board, Biotechnology, CEO, CA, CTO, Data visualization, Fine chemical

Culture Biosciences , a company enabling biotech firms to develop and scale manufacturing processes in the cloud, announced a Series B financing of $80 million led by Northpond Ventures .

Key Points: 
  • Culture Biosciences , a company enabling biotech firms to develop and scale manufacturing processes in the cloud, announced a Series B financing of $80 million led by Northpond Ventures .
  • Todays global capacity falls 100x short of what would be needed to meet the demand for fermentation-based animal protein in 2030.
  • Culture Biosciences is a technology company in South San Francisco, CA, offering biotechnology companies an easier, faster, and cheaper way to do biomanufacturing R&D.
  • Learn more here about career opportunities at Culture and our teams passion for solving the worlds biomanufacturing capacity problem.

iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, September 27, 2021
Therapy, Income, Systemic scleroderma, Conference, Catalog, Hotel manager, Senior management, Growth, Service, IND, Calendar, Glycosylation, Investment, Tumor microenvironment, SEC, Protein, Vaccine, Compliance, Investor, Board of directors, Webcast, Hydroponics, CEO, Disease, NYSE American, Maintenance, History, Biomanufacturing, NYSE, Bioprocess, Infection, Cancer, Partnership, Annual report, CGMP, Sale, Â, Marketing, Chief executive officer, Company, Risk, Severe acute respiratory syndrome coronavirus 2, Drug discovery, Fibrosis, Contract, Time, GLOBE, G&A, CDMO, Cytokine, Board, Fraunhofer Society, COVID-19, Antigen, Research, Lectin, Fine chemical, Pharmaceutical industry, Video game

BRYAN, Texas, Sept. 27, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced its financial results for the fiscal fourth quarter and year ended June 30, 2021.

Key Points: 
  • Fiscal Fourth Quarter and Recent Business Developments:
    In June 2021, iBio established a new drug discovery team based in San Diego.
  • Fiscal Fourth Quarter and Recent Corporate Developments:
    Throughout fiscal 2021 and FY22 year-to-date, iBio increased its bench strength and enhanced its leadership team to support its growth strategy.
  • R&D and G&A expenses for the fourth quarter and full fiscal year 2021 increased significantly over the comparable periods in fiscal year 2020.
  • G&A expense was up $10.6 million to $22.0 million in fiscal 2021, rising $3.5 million to $6.6 million in the fourth quarter.

Global Continuous and Semi-Continuous Bioprocessing Market (2021 to 2030) - by Type of Manufacturer, Company Size, Scale of Operation, Stage of Bioprocess and Geographical Regions - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, Pharmaceutical, Health, GMP, Immortalised cell line, Adoption, Bioprocess, Fermentation, Technology, Chromatography, Filtration, Time, Type, Centrifugation, Industry, COVID-19, Fine chemical

The "Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer, Company Size, Scale of Operation, Stage of Bioprocess, Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer, Company Size, Scale of Operation, Stage of Bioprocess, Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study on the companies having continuous and semi-continuous bioprocessing capabilities.
  • The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
  • In other words, a continuous bioprocessing approach is better suited to the needs of the aseptic manufacturing paradigm that is required for biologics.

Sartorius to Open New Application and Service Hub in Shanghai

Retrieved on: 
Thursday, September 16, 2021
ID Labs production discography, Autocar Sales and Service Building, Investment, Shared services center, Drug discovery, Application, Forward-looking statement, Quality control, Bioprocess, Laboratory, Group, GMP, SCADA, Sartorius, GLP, Mab, Vaccine, Solution, Calibration, Maintenance, District of Columbia Protective Services Division, Research, Federal Data Services Hub, Fine chemical

SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- The life science group Sartorius officially opened its new, significantly expanded Application and Service Hub in Zhangjiang Science City in Shanghai, China. Equipped with the latest innovative instrumentation and offering cutting-edge professional expertise, this Hub covering over 3,000 square meters accommodates the Sartorius Application Center 3.0, the Confidence® Validation Services Laboratory 2.0 and APAC Service Hub. This combined facility is designed as an integrated solution platform to empower and accelerate progress in areas ranging from research to process development to production in the Chinese life sciences and biopharmaceutical industries. "The grand opening of the Application and Service Hub marks a further milestone in Sartorius' development in China and underlines its long-term commitment to this fast-growing market," said Sarah Wang, Head of Sales and Services in China.

Key Points: 
  • Equipped with the latest innovative instrumentation and offering cutting-edge professional expertise, this Hub covering over 3,000 square meters accommodates the Sartorius Application Center 3.0, the Confidence Validation Services Laboratory 2.0 and APAC Service Hub.
  • "The grand opening of the Application and Service Hub marks a further milestone in Sartorius' development in China and underlines its long-term commitment to this fast-growing market," said Sarah Wang, Head of Sales and Services in China.
  • The new Sartorius APAC Service Hub ensures professional after-sales continuity for equipment repair, maintenance, and calibration service.
  • Moreover, the Sartorius Laboratory and Service Center in YETDA Biopark in Yantai, China, is under construction.

Genedata Bioprocess Adopted by Ferring Pharmaceuticals

Retrieved on: 
Tuesday, August 17, 2021
Reproductive medicine, Bioprocess, Software, CMC, Ferring Pharmaceuticals, Immortalised cell line, ROI, D, Biological Technologies Office (DARPA), Investment, USP, Intelligence, Gastroenterology, Development, FD, DSP, Solution, AD, CEO, A-DNA, Doctor of Philosophy, Fine chemical

BASEL, Switzerland, Aug. 17, 2021 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Ferring Pharmaceuticals has adopted Genedata Bioprocess to support end-to-end protein and antibody development processes in their newly formed Biologics Technologies and Development R&D units.

Key Points: 
  • BASEL, Switzerland, Aug. 17, 2021 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Ferring Pharmaceuticals has adopted Genedata Bioprocess to support end-to-end protein and antibody development processes in their newly formed Biologics Technologies and Development R&D units.
  • Genedata will provide a fully integrated enterprise workflow platform to connect data generation, processing, and sharing across Ferring R&D sites.
  • Since 2018, Ferring pharmaceuticals has embarked on strategic investments in biotherapeutic R&D, highlighted by their new state-of-the-art innovation center in Lausanne, Switzerland.
  • "We are very pleased that Ferring has chosen Genedata as their digitalization partner to support their rapidly expanding biotherapeutic drug development operations," said Othmar Pfannes, Ph.D., CEO of Genedata.

Single use Bioprocessing Markets: Media Bags and containers, Bioreactors, Mixers, Assemblies, Cell Culture, Mixing, Storage, Filtration, Purification - Global Forecast 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 16, 2021
Biotechnology, Pharmaceutical, Health, Time, Assembly, Mixer, CMOS, A-DNA, Cros, Bioprocess, Glass, Maintenance, Sterilization, Element, CAGR, Cell culture, Risk, Buffer, MEA, SIP, Investment, CIP, Growth, Technology, Stainless steel, Enzyme, Vaccine, Bacteria, B cell, USD, Bioreactor, LATAM, Fine chemical

The "Global Single use Bioprocessing Market by Product (Media Bags and containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture, Mixing, Storage, Filtration, Purification), End User (Biopharma Companies, CROs, CMOs) - Forecast 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Single use Bioprocessing Market by Product (Media Bags and containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture, Mixing, Storage, Filtration, Purification), End User (Biopharma Companies, CROs, CMOs) - Forecast 2026" report has been added to ResearchAndMarkets.com's offering.
  • Bioprocess utilizes living cells or their components such as enzymes, bacteria, and others to obtain preferred products.
  • The expanded application of single-use bags across biomanufacturing processes drives the market for single-use media bags.
  • The single use bioprocessing market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA).

Teknova to Report Second Quarter 2021 Financial Results on August 11

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Life sciences, Biology, Articles, Biopharmaceuticals, Bioproduction, Bioprocess, Molecular diagnostics, Reagent

HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market.

Key Points: 
  • HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market.
  • ET to discuss the Companys financial results and provide a business update.
  • Participants may access the live webcast on the Investor Relations section of the Teknova website, where it will be archived for 30 days, and at this link: https://edge.media-server.com/mmc/p/avgvftny .
  • Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics.

Global Single-Use Bioprocessing Market Industry Trends, Growth Opportunities and Forecast: 12% CAGR Forecast During 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Biotechnology, Bioprocess, Biotechnology

The "Single-Use Bioprocessing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single-Use Bioprocessing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global single-use bioprocessing market exhibited strong growth during 2015-2020.
  • The increasing demand for pharmaceutical products across the globe is one of the key factors driving the growth of the market.
  • Looking forward, the global single-use bioprocessing market is forecast to grow at a CAGR of around 12% during 2021-2026.

UK Biomanufacturing Team to Spearhead Development of Advanced Controls to Accelerate Drug and Vaccine Manufacturing

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, General Health, Infectious diseases, Health, Pharmaceutical, Biotechnology, Bioprocess, Pharmaceutical industry, Natural sciences, Manufacturing, National Health Service, Medication, NHS Scotland, Articles, Nature, CPI, Pall Corporation, Biopharm Services, SCIEX, BiologIC Technologies, CPI, PALL CORPORATION, BIOPHARM SERVICES, SCIEX, BIOLOGIC TECHNOLOGIES

The project, worth a total of 3.1million, including equipment contributions, has received support from Innovate UK, to platform this advanced technology.

Key Points: 
  • The project, worth a total of 3.1million, including equipment contributions, has received support from Innovate UK, to platform this advanced technology.
  • This will ultimately reduce manufacturing costs and improve product quality, lowering costs to the NHS, and increasing access to life-changing drugs for patients.
  • The continuous bioprocessing module will be linked to the BioSolve Process cost modelling platform of lead partner Biopharm Services.
  • By clarifying the business case using BioSolve Process and actively sharing practical control strategies, the consortium will advance UK biopharmaceutical manufacturing.